.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CB01_Etoposide.Etoposide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CB01_Etoposide.Etoposide| name: | Etoposide |
| ATC code: | L01CB01 | route: | intravenous |
| n-compartments | 2 |
Etoposide is a topoisomerase II inhibitor used as an antineoplastic agent for the treatment of various malignancies including small-cell lung cancer, testicular cancer, lymphoma, and leukemia. It is commonly administered intravenously or orally and is still approved and widely used in cancer chemotherapy.
Pharmacokinetics reported in adult cancer patients following intravenous administration; large multicenter population PK study.
Reif, S, et al., & Jaehde, U (2002). Population pharmacokinetics of etoposide. International journal of clinical pharmacology and therapeutics 40(12) 578–579. DOI:10.5414/cpp40578 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12503821
Nguyen, L, et al., & Canal, P (1998). Population pharmacokinetics of total and unbound etoposide. Cancer chemotherapy and pharmacology 41(2) 125–132. DOI:10.1007/s002800050718 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9443625
Cheng, Y, et al., & Zhou, L (2024). Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). Lung cancer (Amsterdam, Netherlands) 188 107455–None. DOI:10.1016/j.lungcan.2023.107455 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38224653